or Try an Advanced Search...

    Technical Analysis for KZIA - Kazia Therapeutics Limited

    Grade Last Price % Change Price Change
    F 0.29 -0.76% 0.00
    KZIA closed down 1.23 percent on Wednesday, May 8, 2024, on 13 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical KZIA trend table...
    Date Alert Name Type % Chg
    Stochastic Buy Signal Bullish -0.76%
    Wide Bands Range Expansion -0.76%
    Oversold Stochastic Weakness -0.76%
    NR7 Range Contraction -1.98%
    Narrow Range Bar Range Contraction -1.98%
    Wide Bands Range Expansion -1.98%
    Oversold Stochastic Weakness -1.98%
    Stochastic Reached Oversold Weakness 2.46%
    Inside Day Range Contraction 2.46%
    Wide Bands Range Expansion 2.46%
    Older End-of-Day Signals for KZIA ...

       Recent Intraday Alerts

    Alert Time
    Down 3% about 2 hours ago
    Down 2 % about 2 hours ago
    Down 1% about 2 hours ago
    Up 1% about 2 hours ago
    Down 5% about 24 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    KZIA Chart by TradingView
    Basic chart:

    Profile

    Kazia Therapeutics Limited Description

    Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Cancer Cancer Treatment ATM Chemotherapy Ovarian Cancer Blastoma Cancer Cell Glioma Neuroblastoma Cytoskeleton Diffuse Intrinsic Pontine Glioma Novogen Pharmaceutical Research

    Is KZIA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 1 KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS
    Apr 12 Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
    Mar 13 Kazia announces presentation of new data at AACR Annual Meeting
    Feb 21 Kazia concludes Phase 1 study for paxalisib early due to promising data
    Feb 21 Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
    Jan 18 KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS
    Dec 15 Kazia Therapeutics files to sell 591,697 ADSs for holders
    Dec 5 Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
    Dec 1 Kazia Therapeutics falls after announcing $2M direct offering
    Dec 1 Kazia Therapeutics Announces $2 Million Registered Direct Offering
    See more KZIA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 1.3899
    52 Week Low 0.1866
    Average Volume 470,512
    200-Day Moving Average 0.56
    50-Day Moving Average 0.30
    20-Day Moving Average 0.33
    10-Day Moving Average 0.31
    Average True Range 0.04
    RSI (14) 42.53
    ADX 19.91
    +DI 14.94
    -DI 23.07
    Chandelier Exit (Long, 3 ATRs) 0.36
    Chandelier Exit (Short, 3 ATRs) 0.38
    Upper Bollinger Bands 0.41
    Lower Bollinger Band 0.25
    Percent B (%b) 0.22
    BandWidth 47.68
    MACD Line -0.01
    MACD Signal Line 0.00
    MACD Histogram -0.0113
    Fundamentals Value
    Market Cap 7.62 Million
    Num Shares 26.4 Million
    EPS -0.73
    Price-to-Earnings (P/E) Ratio -0.40
    Price-to-Sales 12881.51
    Price-to-Book 0.96
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.33
    Resistance 3 (R3) 0.33 0.32 0.33
    Resistance 2 (R2) 0.32 0.30 0.32 0.32
    Resistance 1 (R1) 0.30 0.30 0.29 0.30 0.32
    Pivot Point 0.29 0.29 0.28 0.29 0.29
    Support 1 (S1) 0.27 0.28 0.27 0.27 0.26
    Support 2 (S2) 0.26 0.27 0.26 0.26
    Support 3 (S3) 0.24 0.26 0.25
    Support 4 (S4) 0.25